ESR1 and breast carcinoma: Several studies have highlighted the predominant transcriptional activity of the HAS2 gene in ER− aggressive breast cancer cell lines compared to the limited expression of HAS3 in nonaggressive ER+ cell lines [91,92,93] (Table 1).